Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON45144
NL-OMON45144
Completed
Not Applicable

Identification of muscle-invasive bladder cancer patients who will not benefit from neoadjuvant chemotherapy using circulating tumor cells. - CTCs to guide neoadjuvant chemotherapy in bladder cancer.

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites320 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsmuscle invasive bladder cancermuscle invasive bladder carcinoma1003836410004994

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
muscle invasive bladder cancer
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
320
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- Histopathologically confirmed muscle\-invasive urothelial carcinoma of the bladder.
  • •\- Clinical stage T2\-T4a N0\-N1 bladder cancer.
  • •\- Candidate for radical local treatment consisting of radical cystectomy.
  • •\- Age \* 18 years.
  • •\- Signed informed consent

Exclusion Criteria

  • •\- Muscle\-invasive bladder cancer other than urothelial carcinoma (adenocarcinoma, squamous cell carcinoma, small cell carcinoma, neuro\-endocrine tumor).
  • •\- History of other malignant disease with a tumor\-free interval of \* 5 years.
  • •\- Known or suspected coincidental prostate cancer.
  • •\- Metastatic disease at staging, as assessed by a CT\-scan of thorax and abdomen
  • •\- Local or systemic adjuvant treatment after radical cystectomy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Identification of muscle-invasive bladder cancer patients who will not benefit from neoadjuvant chemotherapy using circulating tumor cells.
NL-OMON23413Erasmus MC260
Active, not recruiting
Not Applicable
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2011-001819-30-DESanochemia Pharmazeutika AG220
Active, not recruiting
Not Applicable
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2011-001819-30-ATSanochemia Pharmazeutika AG220
Completed
Phase 2
Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy(Hypericin PDD)C67Malignant neoplasm of bladder
DRKS00003324Sanochemia Pharmazeutika AG227
Completed
Phase 3
The IMAGE1 S* Non-Muscle-Invasive bladder cancer study: A multicenter international randomized controlled study to compare the outcome using the IMAGE1 S* System versus White Light Imaging (WLI) during TURB of Non-Muscle-Invasive Bladder Cancer (NMIBC).
NL-OMON47283Academisch Medisch Centrum100